Liran Belenzon from BenchSci
from The Hard Part with Evan McCann Hosted by Evan McCann
Liran Belenzon is the Co-Founder and CEO of BenchSci. BenchSci's mission is to exponentially increase the speed and quality of life-saving R&D to improve patients' health. They do this by applying cutting-edge AI to understand how disease biology works at scale throughout the drug discovery pipeline to solve the number one reason why drug discovery projects fail — getting the biology wrong. ASCEND, their disease biology GenAI platform, understands the entire history of biomedical experiments to create a scalable AI assistant for preclinical organizations. Takeaways The genesis story of BenchSci. Thoughts on commercialization and how to do it well. How Liran has scaled with the company as a leader and founder. Step changes in headcount. How BenchSci navigates in-person, remote and hybrid work. Liran's contrarian thoughts on raising money and how he has raised $200M+. Why you should only do investor updates for investors and not potential investors. How AI has changed over the last 8+ years of BenchSci's journey. Building a network as an immigrant founder. Scaling product offerings. Working and selling into big pharma and research teams. Hiring for BenchSci's unique intersection of AI and bio. Chapters 00:00 The Genesis of BenchSci 03:12 Navigating the Drug Discovery Landscape 05:47 Commercialization Challenges and Strategies 08:59 Scaling as a Founder 11:59 Remote Work Dynamics 14:51 Mastering the Fundraising Process 19:52 The Evolution of AI in Drug Discovery 23:12 Understanding the Drug Discovery Process 25:54 Building Trust with Researchers 28:50 Overcoming Networking Challenges 32:14 Scaling Product Offerings 35:01 Hiring for a Unique Intersection 36:57 Personal Reflections and Future Outlook Keywords BenchSci, drug discovery, AI, commercialization, startup, scaling, fundraising, remote work, biology, technology
Embed this episode
No transcript yet.